INDV 13F position history: Howard Marks - Oaktree Capital Management
Indivior Pharmaceuticals, Inc, as reported in Howard Marks - Oaktree Capital Management’s quarterly 13F filings. See all fund managers holding INDV.
| Quarter | Activity | Shares | Value | % of portfolio | Reported price | |
|---|---|---|---|---|---|---|
| Q2 2026 | Trimmed | 6,127,212 | $251,399,508 | 6.65% | $41.03 | Filing |
| Q1 2026 | New | 6,984,102 | $212,875,428 | 4.94% | $30.48 | Filing |